WO2008056188A3 - Nouveaux composés et leurs procédés de production - Google Patents

Nouveaux composés et leurs procédés de production Download PDF

Info

Publication number
WO2008056188A3
WO2008056188A3 PCT/GB2007/050679 GB2007050679W WO2008056188A3 WO 2008056188 A3 WO2008056188 A3 WO 2008056188A3 GB 2007050679 W GB2007050679 W GB 2007050679W WO 2008056188 A3 WO2008056188 A3 WO 2008056188A3
Authority
WO
WIPO (PCT)
Prior art keywords
production
diseases
methods
novel compounds
cancer
Prior art date
Application number
PCT/GB2007/050679
Other languages
English (en)
Other versions
WO2008056188A2 (fr
Inventor
Christine Martin
Original Assignee
Biotica Tech Ltd
Christine Martin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0622342.4A external-priority patent/GB0622342D0/en
Priority claimed from GB0720875A external-priority patent/GB0720875D0/en
Priority to EP07824891A priority Critical patent/EP1973883B1/fr
Priority to CA002669047A priority patent/CA2669047A1/fr
Priority to MX2009004775A priority patent/MX2009004775A/es
Priority to US12/513,967 priority patent/US8492370B2/en
Application filed by Biotica Tech Ltd, Christine Martin filed Critical Biotica Tech Ltd
Priority to JP2009535815A priority patent/JP2010509306A/ja
Priority to ES07824891T priority patent/ES2389740T3/es
Priority to AU2007319014A priority patent/AU2007319014B2/en
Priority to BRPI0718564-2A priority patent/BRPI0718564A2/pt
Publication of WO2008056188A2 publication Critical patent/WO2008056188A2/fr
Publication of WO2008056188A3 publication Critical patent/WO2008056188A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des analogues d'ansamycine trouvant une utilité, par exemple, dans le traitement du cancer, de tumeurs malignes des lymphocytes B, de la malaria, d'une infection fongique, de maladies du système nerveux central et de maladies neurodégénératives, de maladies dépendant de l'angiogenèse ou de maladies auto-immunes, ou dans le traitement préventif du cancer. La présente invention concerne également des procédés de production de ces composés ainsi que leur utilisation en médecine.
PCT/GB2007/050679 2006-11-09 2007-11-09 Nouveaux composés et leurs procédés de production WO2008056188A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
BRPI0718564-2A BRPI0718564A2 (pt) 2006-11-09 2007-11-09 Composto, métodos para preparar um composto, para gerar análogos de ansamicina, para tratar uma doença, e para produzir um composto, análogo de ansamicina, composição farmacêutica, uso de um análogo de ansamicina, cepa engenheirada, e, uso de uma cepa engenheirada.
AU2007319014A AU2007319014B2 (en) 2006-11-09 2007-11-09 Novel compounds and methods for their production
CA002669047A CA2669047A1 (fr) 2006-11-09 2007-11-09 Nouveaux composes et leurs procedes de production
MX2009004775A MX2009004775A (es) 2006-11-09 2007-11-09 Nuevos compuestos y metodos para su produccion.
US12/513,967 US8492370B2 (en) 2006-11-09 2007-11-09 Compounds and methods for their production
EP07824891A EP1973883B1 (fr) 2006-11-09 2007-11-09 Nouveaux composés et leurs procédés de production
JP2009535815A JP2010509306A (ja) 2006-11-09 2007-11-09 新規化合物及びそれらの製造方法
ES07824891T ES2389740T3 (es) 2006-11-09 2007-11-09 Nuevos compuestos y procedimientos para su producción

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0622342.4A GB0622342D0 (en) 2006-11-09 2006-11-09 Novel compounds and methods for their production
GB0622342.4 2006-11-09
GB0720875.4 2007-10-24
GB0720875A GB0720875D0 (en) 2007-10-24 2007-10-24 Novel compounds and methods for their production

Publications (2)

Publication Number Publication Date
WO2008056188A2 WO2008056188A2 (fr) 2008-05-15
WO2008056188A3 true WO2008056188A3 (fr) 2008-07-31

Family

ID=39362724

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/050679 WO2008056188A2 (fr) 2006-11-09 2007-11-09 Nouveaux composés et leurs procédés de production

Country Status (10)

Country Link
US (1) US8492370B2 (fr)
EP (1) EP1973883B1 (fr)
JP (1) JP2010509306A (fr)
KR (1) KR20090075856A (fr)
AU (1) AU2007319014B2 (fr)
BR (1) BRPI0718564A2 (fr)
CA (1) CA2669047A1 (fr)
ES (1) ES2389740T3 (fr)
MX (1) MX2009004775A (fr)
WO (1) WO2008056188A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2121957A4 (fr) * 2007-01-26 2010-11-10 Kosan Biosciences Inc Macrolactames obtenus par biosynthèse modifiée
KR101097850B1 (ko) 2009-02-24 2011-12-23 한국생명공학연구원 젤다나마이신 생합성 조절유전자 변이주 및 이를 이용한 젤다나마이신 생산방법
CN117695374A (zh) * 2024-01-25 2024-03-15 超越健康科技(浙江)有限公司 一种用于治疗帕金森病的生物药物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005061461A1 (fr) * 2003-12-24 2005-07-07 Kyowa Hakko Kogyo Co., Ltd. Inhibiteurs diriges a l'encontre de membres de la famille de la proteine de choc thermique 90 (hsp90)
WO2007001049A1 (fr) * 2005-06-29 2007-01-04 Kyowa Hakko Kogyo Co., Ltd. Dérivé de l'ansamycine benzénoïde
WO2007074347A1 (fr) * 2005-12-24 2007-07-05 Biotica Technology Ltd. Noveaux composes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06510913A (ja) * 1992-01-06 1994-12-08 フアイザー・インコーポレイテツド ４，５‐ジヒドロゲルダナマイシン及びそのヒドロキノンの製造及び使用
AU2003217393B8 (en) * 2002-02-08 2009-06-25 Conforma Therapeutics Corporation Ansamycins having improved pharmacological and biological properties
ES2409351T3 (es) * 2003-12-23 2013-06-26 Infinity Discovery, Inc. Análogos de ansamicinas que contienen benzoquinona para el tratamiento de cáncer
EP1863769A4 (fr) * 2005-03-11 2009-03-18 Univ Colorado Inhibiteurs hsp90, procedes de realisation et d'utilisation correspondants
CN101012196A (zh) * 2006-12-27 2007-08-08 中国人民解放军军事医学科学院毒物药物研究所 芳香化格尔德霉素类衍生物及其制备方法和用途
EP2121957A4 (fr) * 2007-01-26 2010-11-10 Kosan Biosciences Inc Macrolactames obtenus par biosynthèse modifiée

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005061461A1 (fr) * 2003-12-24 2005-07-07 Kyowa Hakko Kogyo Co., Ltd. Inhibiteurs diriges a l'encontre de membres de la famille de la proteine de choc thermique 90 (hsp90)
WO2007001049A1 (fr) * 2005-06-29 2007-01-04 Kyowa Hakko Kogyo Co., Ltd. Dérivé de l'ansamycine benzénoïde
EP1897871A1 (fr) * 2005-06-29 2008-03-12 Kyowa Hakko Kogyo Co., Ltd. Dérivé de l'ansamycine benzénoïde
WO2007074347A1 (fr) * 2005-12-24 2007-07-05 Biotica Technology Ltd. Noveaux composes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LI M G ET AL: "Isolation and Structure Elucidation of Autolytimycin, A new Compound Produced by Streptomyces Autolyticus JX-47", CHINESE CHEMICAL LETTERS, XX, XX, vol. 12, no. 10, 1 January 2001 (2001-01-01), pages 903 - 906, XP002988236, ISSN: 1001-8417 *
STEAD P ET AL: "Discovery of novel ansamycins possessing potent inhibitory activity in a Cell-based Oncostatin M signalling assay", JOURNAL OF ANTIBIOTICS, JAPAN ANTIBIOTICS RESEARCH ASSOCIATION, TOKYO, JP, vol. 53, no. 7, 1 July 2000 (2000-07-01), pages 657 - 663, XP002988238, ISSN: 0021-8820 *
TAKATSU T ET AL: "Reblastatin, a novel benzenoid ansamycin-type cell cacle inhibitor", JOURNAL OF ANTIBIOTICS, JAPAN ANTIBIOTICS RESEARCH ASSOCIATION, TOKYO, JP, vol. 53, no. 11, 1 November 2000 (2000-11-01), pages 1310 - 1312, XP002988237, ISSN: 0021-8820 *

Also Published As

Publication number Publication date
JP2010509306A (ja) 2010-03-25
EP1973883A2 (fr) 2008-10-01
US20110021481A1 (en) 2011-01-27
ES2389740T3 (es) 2012-10-31
CA2669047A1 (fr) 2008-05-15
AU2007319014A1 (en) 2008-05-15
KR20090075856A (ko) 2009-07-09
WO2008056188A2 (fr) 2008-05-15
US8492370B2 (en) 2013-07-23
AU2007319014B2 (en) 2013-03-28
BRPI0718564A2 (pt) 2014-03-11
EP1973883B1 (fr) 2012-07-11
MX2009004775A (es) 2009-05-21

Similar Documents

Publication Publication Date Title
WO2005079756A3 (fr) Methodes et compositions de traitement de troubles psychiatriques
JO2858B1 (en) Pharmaceutical dosage images
WO2008095086A3 (fr) Topiramate plus naltrexone pour le traitement de troubles addictifs
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
WO2011041582A3 (fr) Procédés de modulation de l'autophagie par la modulation de produits géniques inhibant l'autophagie
WO2006127898A3 (fr) (s)-n-methylnaltrexone
WO2008136976A3 (fr) Composés pour traiter des troubles prolifératifs
WO2008104306A3 (fr) Amides de 4-aryl-1,4-dihydro-1,6-naphthyridine substitués et utilisation de ceux-ci
UA108198C2 (uk) Заміщені 2-ацетамідо-5-арил-1,2,4-триазолони та їх застосування
MX2007002470A (es) Fenilaminotiazoles sustituidos y su uso.
WO2010096394A3 (fr) Véhicules de médicaments à base de protéine marqués par aldéhyde et procédés d'utilisation
WO2006009765A3 (fr) Procedes d'identification et d'utilisation de composes adaptes au traitement de cellules cancereuses resistantes aux medicaments
WO2009004491A3 (fr) Préparation d'oxycodone
WO2006034512A3 (fr) Composes a base de quinoleine et de quinazoline a substitution de phenylique pour le traitement du diabete
WO2008104590A3 (fr) Nouvelle forme dosifiée
GEP20115293B (en) Isolated extract of walnuts, process for its obtaining and its use
MX2009000991A (es) Uso de escina.
WO2010088527A3 (fr) Peptides et nanoparticules pour des applications thérapeutiques et diagnostiques
WO2008021346A3 (fr) Palipéridone pure et ses procédés d'obtention
WO2011151789A3 (fr) Chalcones substituées par aminoalkyle et analogues et dérivés associés
WO2007128829A3 (fr) Nouveaux composés
AU2013212209A8 (en) (1R,4R) 7-oxo-2-azabicyclo[2.2.2]oct-5-ene and derivatives thereof
WO2008056188A3 (fr) Nouveaux composés et leurs procédés de production
MY149864A (en) Flavouring-containing pharmaceutical formulations with improved pharmaceutical properties
WO2010119450A3 (fr) Procédé amélioré pour la préparation de la desmopressine ou de ses sels pharmaceutiquement acceptables

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780041913.6

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2007824891

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07824891

Country of ref document: EP

Kind code of ref document: A2

WWP Wipo information: published in national office

Ref document number: 2007824891

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007319014

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1558/KOLNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/004775

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2009535815

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2669047

Country of ref document: CA

Ref document number: 1020097009593

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007319014

Country of ref document: AU

Date of ref document: 20071109

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12513967

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0718564

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090507